

| Recovery OPO GLDP Allocation Via UPENN ⋈ nPOD □ Age (years) 35 DCD YES □ NO ⋈ Race Caucasion DBD YES ⋈ NO □ Sex M ⋈ F□ Admission to Cross Clamp 49 Hours 44 Mins. ABO (Rh) AB+ Cross Clamp Time 06/02/2019 22:48 EST BMI (Kg/m²) Weight (kg) 23.98 75.8 Cold Ischemia Time* 11 Hours 32 Mins. | O ⊠ O □ s 44 Mins. | | |
|---|-----------------------------|--|--|
| Race Caucasion DBD YES NO □ Sex M ⋈ F□ Admission to Cross Clamp 49 Hours 44 Mins. ABO (Rh) AB+ Cross Clamp Time 06/02/2019 22:48 EST BMI (Kg/m²) 23.98 Cold Ischemia 11 Hours 32 Mins | O Mins. | | |
| Sex M ⋈ F□ Admission to Cross Clamp 49 Hours 44 Mins. ABO (Rh) AB+ Cross Clamp Time 06/02/2019 22:48 EST BMI (Kg/m²) 23.98 Cold Ischemia 11 Hours 32 Mins | Mins. | | |
| Clamp Hours Mins. | s Mins. | | |
| BMI (Kg/m²) 23.98 Cold Ischemia 11 Hours 32 Mins | 22:48 EST | | |
| l i laure l Muse | | | |
| Height (cm) 177.8 | 32 Mins. | | |
| Cause of Death C VA / Stroke Preservation UW M HTK Solution | тк□ | | |
| Mechanism of InjuryIntracranial HemorrhageOrgans Recovered LungHeart⋈Kidney⋈Liver☑Pancreas⋈Liver☑Intestine□ | Pancreas ⊠ | | |
| Cardiac Arrest/Downtime Yes □ Intraoperative time lapse from liver to pancreas removal from the peritoneal cavity: Intraoperative time lapse from liver to pancreas removal from the peritoneal | Mins. | | |
| | Kidney Pancreas Intestine | | |
| Total Est. Downtime 0 Blood Culture No Growth | | | |
| Date /Time of Admission 5/31/2019 21:04 EST PHS High Risk YES □ NO ☒ | YES □ NO ⊠ | | |
| Acute Lung Injury No ARDS | | | |

^{*}Cold Ischemia time is calculated from time of cross clamp to start of enzyme perfusion for islet isolation.



Medical History:

| | | Duration | Medications | Compliance | | |
|--------------------|-------|------------|-----------------------|------------|--|--|
| Type of Diabetes | None | | | | | |
| History of cancer | None | | | | | |
| CAD | None | | | | | |
| Hypertension | None | | | | | |
| Hyperlipidemia | None | | | | | |
| Autoimmune disease | None | | | | | |
| Family History | CAD □ | Diabetes 🛛 | Auto immune disease 🗆 | Others: | | |
| | | Father | | | | |
| Surgical History: | | | | | | |
| | None | | | | | |
| | | | | | | |
| Comments: | | | | | | |

Hemodynamic Profile

| Average BP During Hospitalization (mmHg) | 135/80 | |
|--|-------------|----------------------|
| Average Low BP During Hospitalization | 60/32 | Duration: 30 minutes |
| Average BP in OR (mmHg) | 115/70 | |
| Average Low BP in OR (mmHg) | 57/33 | Duration: 1 minute |
| Average HR in OR (bpm) | 115 | |
| ABG-pH range | 7.42 – 7.29 | |

INTERVENTION

Blood Products/Meds Transfused Before Organ Recovery

| Product | Amount (ml) | Units | Total (ml) | |
|---------------------------|-------------|-----------------------------------|------------|--|
| Fresh Frozen Plasma | | | | |
| PRBCs | | | | |
| Platelets | | | | |
| Norepinephrine (Levophed) | | 10 mcg/min 24 hours before OR | | |
| Vasopressin | | 0.04 units/min 24 hours before OR | | |
| Neo-Synephrine | | | | |
| Epinephrine | | | | |
| Phenylephrine | | | | |
| Dopamine | | | | |



Blood Products/Meds Transfused Intraoperative

| Product | Amount (ml) | Units | Total (ml) |
|--------------------------------|-------------|--------|------------|
| Fresh Frozen Plasma | | | |
| PRBCs | | | |
| Platelets | | | |
| Norepinephrine (Levophed) | | | |
| Vasopressin | | | |
| Neo-Synephrine (phenylephrine) | | | |
| Epinephrine | | | |
| Dopamine | | | |
| Heparin | | 30,000 | |

Initial Autoantibody Screening (nPOD): ELISA

| GAD-65 | IA-2 |
|--------|------|
| ND | ND |

Confirmatory results: Radioimmuno Assay (RIA)

| | GAD-65 (unit/ml) | IA-2 (unit/ml) | Insulin AAB (unit/ml) | ZnT8 (unit/ml) |
|-----------------------|---------------------|-------------------|--------------------------|-------------------|
| Results | 0 | 0 | 0.003 | 0.004 |
| Cut-off values | 20 | 5 | 0.010 | 0.020 |

^{*}Sample obtained at time of organ recovery.

| | C-peptide (ng/ml) | Proinsulin |
|---------|----------------------|------------|
| Results | 7.01 | ND |

^{*}Sample obtained at time of organ recovery.

HLA (OPO)*

| Class 1 | Α | 11 | 30 | Class II | DR | 01:03 | 7 |
|----------|-----|----------|----|----------|------|----------|----------|
| Class I | В | 13 | 35 | | DR51 | Negative | Negative |
| | | | | | | | _ |
| | С | 04 | 06 | | DR52 | Negative | Negative |
| | Bw4 | Positive | | | DR53 | 53 | 53 |
| | Bw6 | Positive | | | DQB1 | 2 | 5 |
| | | | | | DQA1 | 01 | 02 |
| | | | | | DPB1 | 04:01 | 04:01 |
| | | | | | | | |
| Comment: | | | | | | | |



Confirmatory HLA (UPENN)*

| Class 1 | Α | 11:01 | 30:01 | Class II | DRB1 | 01:03 | 07:01 |
|---------|---|-------|-------|----------|------|-------|-------|
| | В | 13.02 | 35.01 | | DRB3 | | |
| | С | 04:01 | 06:02 | | DRB4 | | 01:03 |
| | | | | | DRB5 | | |
| | | | | | DQB1 | 02:02 | 05:01 |
| | | | | | DQA1 | 01:01 | 02:01 |
| | | | | | DPB1 | 04:01 | |
| | | | | | DPA1 | 01:03 | |

^{*}HLA typing performed using NGS

Infectious Disease Serology

| | | Hemo/Plasma Dilution Status | |
|-----------------|--------------|-----------------------------|---------------|
| Test | Result | Qualified | Non-Qualified |
| EBV IgG | Positive | ✓ | |
| EBV IgM | Negative | ✓ | |
| CMV | Negative | ✓ | |
| HBcAb | Non-Reactive | ✓ | |
| HBsAg | Non-Reactive | ✓ | |
| HCV Ab | Non-Reactive | ✓ | |
| HIV I/II | Non-Reactive | ✓ | |
| Syphilis | Non-Reactive | ✓ | |
| Procleix Ultrio | | | |
| Ultrio HBV | Non-Reactive | ✓ | |
| Ultrio HCV | Non-Reactive | ✓ | |
| Ultrio HIV | Non-Reactive | ✓ | |
| Toxoplasma Ab | Negative | ✓ | |



Laboratory Panel

| | Initial | Peak | Terminal |
|-------------------------------|---------|------|----------|
| Na (mEq/L) (135-145) | 139 | 155 | 146 |
| Creatinine (<1.5) | 1.21 | 1.21 | 1.03 |
| Glucose (mg/dL) (60-150) | 124 | 242 | 242 |
| HbA1C% | 5.4 | | |
| Total bilirubin (0-1.0) | 0.6 | 1.0 | 0.6 |
| SGOT (AST) (0-40) | 67 | 83 | 76 |
| SGPT (ALT) (5-35) | 53 | 53 | 42 |
| Alkaline phosphatase (45-110) | 61 | 61 | 52 |
| Serum Amylase (23-851) | 88 | 88 | 39 |
| Serum Lipase (0-80) | 146 | 214 | 81 |
| WBC (THO/uL) (4.5-11.0) | 11.5 | 19.8 | 19.8 |
| Hgb (g/dL) (12-16) | 13.4 | 13.4 | 13.4 |
| Platelets (THO/uL) (150-350) | 256 | 256 | 201 |
| INR (<2.0) | 1.27 | 1.39 | 1.39 |

Urinalysis

| | 1 st | 2 nd | 3 rd | 4 th |
|---------|-----------------|-----------------|-----------------|-----------------|
| Glucose | 100 | >1000 | | |

Medications During Hospitalization

| | - | | | |
|----------------------------|--------------------------------------|---------|--|--|
| Steroids** | | | | |
| Diuretics | | | | |
| T3 Protocol | | | | |
| T4 Protocol* | 10 mcg/hr started 24 hours before OR | | | |
| Insulin** | | | | |
| Antihypertensive | | | | |
| Vasodilators | | | | |
| DDAVP** | | | | |
| Total parenteral nutrition | | | | |
| Other | | Specify | | |

^{*}T4 protocol: Levothyroxine, (20 mcgs), Solumedrol (2 gms,) Dextrose 50%, (1 amp), Regular Insulin (20u), Vasopressin (1 unit)

Mi Z, Novitzky D, Collins JF, Cooper D KC. The optimal hormonal replacement modality selection for multiple organ procurement from brain-dead organ donors. Clinical Epidemiology 2015:7 17-27.

^{**} Excluding T4 Protocol